Tellgen(SZ:300642)2018-04-26 16:00Financial Performance - Total revenue for Q1 2018 was ¥53,428,703.11, representing a 21.97% increase compared to ¥43,803,767.30 in the same period last year[7]. - Net profit attributable to shareholders was ¥12,928,855.31, a 2.04% increase from ¥12,670,123.59 year-on-year[7]. - Basic earnings per share decreased by 25.00% to ¥0.21 from ¥0.28 in the previous year[7]. - The company's operating revenue for Q1 2018 was ¥53,428,703.11, an increase from ¥43,803,767.30 in the same period last year, representing a growth of approximately 21.5%[70]. - Net profit for Q1 2018 reached ¥13,715,124.45, compared to ¥13,211,723.06 in Q1 2017, reflecting an increase of about 3.8%[70]. Cash Flow - The net cash flow from operating activities improved significantly to ¥9,478,015.40, compared to a negative cash flow of ¥1,066,084.67 in the same period last year[7]. - The net cash flow from operating activities was ¥9,951,998.16, a significant improvement from a negative cash flow of ¥422,246.90 in the previous year[78]. - Cash inflows from investment activities totaled ¥120,432,958.91, up from ¥60,163,989.04 in the prior year, indicating a 100.4% increase[75]. - Cash outflows for investment activities were ¥260,509,140.78, compared to ¥127,211,751.88 in the same period last year, resulting in a net cash flow from investment activities of -¥140,076,181.87[75]. - The net cash flow from investment activities was -¥117,583,634.79, worsening from -¥64,617,099.71 year-over-year[78]. Assets and Liabilities - Total assets increased by 4.39% to ¥976,218,069.61 from ¥935,164,370.10 at the end of the previous year[7]. - The company's total assets as of the end of the period amounted to CNY 965,533,247.02, an increase from CNY 924,271,063.18 at the beginning of the period[64]. - Total liabilities were CNY 25,575,720.10, slightly down from CNY 26,426,309.24[64]. - The company's equity attributable to shareholders reached CNY 939,957,526.92, up from CNY 897,844,753.94[64]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,176[14]. - The largest shareholder, Yao Jian'er, holds 20.03% of shares, totaling 12,131,000 shares, with 950,000 shares pledged[14]. - The second-largest shareholder, Lingfei Group, owns 13.80% of shares, amounting to 8,358,000 shares[14]. - The top ten shareholders collectively hold significant stakes, with the top three alone accounting for over 43% of total shares[14]. - The company has a clear strategy for shareholder management, with significant stakes held by related parties[15]. Research and Development - The company is focused on developing high-end in vitro diagnostic products to adapt to changes in industry regulations and market needs[10]. - The company is committed to a structured R&D management model to mitigate risks associated with new product development and registration[11]. - The company continues to advance its R&D projects as planned, contributing to its core technology and competitive capabilities[24]. Stock and Dividends - The company commits to distribute cash dividends of no less than 20% of the annual distributable profits achieved in the previous year for the next three years[39]. - The company plans to cumulatively distribute cash dividends of no less than 30% of the average annual distributable profits over the three years[39]. - The company has a stock repurchase commitment to stabilize share prices, with conditions for repurchase outlined in compliance with relevant laws and regulations[40]. Compliance and Governance - The company has established guidelines to prevent conflicts of interest and ensure compliance with industry regulations[43]. - The company will publicly disclose any violation of the reduction intention and apologize to shareholders and the public[37]. - The company must announce any share reduction three trading days in advance and comply with relevant securities exchange rules[38].